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1. Introduction
The epidemiology of end-stage renal disease (ESRD) varies considerably worldwide. In
Thailand, the incidence of ESRD on renal replacement therapy (RRT) increased from 78.9 per
million populations in 1999 to 552.8 per million populations in 2009. The yearly incidence of
all RRT modalities increased by an average of 34.8% from 2007 to 2009 [1]. According to the
estimation by the International Diabetes Foundation, by the year 2025 the frequency of diabetes
is expected to increase threefold worldwide [2]. Diabetic nephropathy is the most common
cause of ESRD [3], representing 30-47% of the United States and Asian populations undergoing
long-term maintenance hemodialysis [4, 5]. Disparities in the incidence of ESRD due to
diabetes among ethnic groups have existed for many years, but the magnitude may be
increasing.
In the United States, from 1990 to 1996, the age-adjusted diabetes-related ESRD incidence
increased from 299.0 to 343.2 per 100,000 diabetic patients. However, from 1996 to 2006, the
age-adjusted diabetes-related ESRD incidence decreased by 3.9% per year from 343.2 to 197.7
per 100,000 diabetic patients [6]. Diabetes-related ESRD incidence in the diabetic population
has declined in all age-groups, probably because of a reduction in the prevalence of ESRD risk
factors, improved treatment and care, and other factors. An alternative explanation for the
decline in diabetes-related ESRD incidence in the diabetic population might be that the patients
are not surviving long enough to develop ESRD, which occurs typically between 10 and 15
years after the onset of the disease. Premature mortality among ESRD patients with diabetes
as a result of the increasing prevalence of coronary heart disease and stroke by tenfold could
reduce the number of people who ultimately develop ESRD [7, 8]. Even though diabetes-
related ESRD incidence in the population with diabetes has decreased since 1996, diabetes-
related ESRD incidence in the general population and the number of persons initiating
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treatment for kidney failure each year who have diabetes listed as a primary cause continue
to increase [5, 9]. In Europe, data from the European Renal Association-European Dialysis and
Transplant Association (ERA-EDTA) Registry shows an 11.9% annual increase in patients with
type 2 diabetes entering RRT [10]. The most recent report of the Thailand RRT Registry shows
a prevalence of diabetes among patients with ESRD of 47.6% and an incidence of 47.7%. The
majority of patients with ESRD secondary to diabetes (51.0%) are treated by hemodialysis,
45.1% by peritoneal dialysis, and 3.9% have functioning renal transplants [1].
Diabetes-related ESRD is a costly and disabling condition with a high mortality rate. These
patients are at a higher risk of mortality, mostly from cardiovascular complications, than other
patients with diabetes. Apart from cardiac complications, the patients are subject to a wide
range of vascular (e.g., peripheral vascular disease, stroke) and infectious complications.
Patients with ESRD due to diabetes challenge the nephrologists because they have the greatest
number of comorbid conditions, and the greatest dependency during daily activities. The goal
of therapy is to improve quality of life, as well as reduce mortality. Attention to several basic
principles helps to guide therapy: control of hypertension, control of hyperglycemia, control
of lipid abnormalities, treatment of malnutrition, and attention to the effects of erythropoietin.
Current cardio- and renoprotective treatment for diabetic nephropathy without ESRD includes
optimization of glycemic control. Early intensive glycemic interventions reduce cardiovascular
events as well as nephropathy by about half when compared with a conventional glycemic
treatment. However, hypoglycemia is common because of impaired renal gluconeogenesis,
malnutrition, chronic inflammation, decrease renal insulin clearance and the increased half-
life of hypoglycemic agents [11]. Therefore, data are scarce on how diabetes should best be
treated in patients in ESRD. In this chapter, we summarize the current evidence for glucose
metabolism and glycemic control in diabetic patients on dialysis.
2. Glucose metabolism in dialysis
Hyperglycemia is an important factor in the progression of diabetic nephropathy. Early
functional changes in diabetic nephropathy include glomerular hyperfiltration, glomerular
and tubular epithelial hypertrophy, and the development of microalbuminuria, followed by
the development of glomerular basement membrane (GBM) thickening, accumulation of
mesangial matrix, and overt proteinuria, eventually leading to glomerulosclerosis and ESRD.
Hyperglycemia-induced metabolic and hemodynamic pathways are recognized to be media‐
tors of kidney injury [4].
Glucose transport activity is an important modulator of extracellular matrix formation by
mesangial cells. Glucose transporter-1 (GLUT-1) regulates glucose entry into renal cells.
Glucose and its metabolites subsequently activate metabolic pathways, and these pathways
contribute to mesangial expansion and mesangial cell matrix-production, mesangial cell
apoptosis and structural changes [12]. This may result from a similar increase in the mesangial
cell glucose concentration, since similar changes in mesangial function can be induced in a
normal glucose milieu by over-expression of GLUT1 [13]. Multiple biochemical pathways have
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been postulated that explain how hyperglycemia causes tissue damage including: non-
enzymatic glycosylation that generates advanced glycosylation end products (AGE); activa‐
tion of protein kinase C (PKC); and acceleration of the polyol pathway. Oxidative stress also
seems to be a common theme. These pathways ultimately lead to increased renal albumin
permeability and extracellular matrix accumulation, resulting in increasing proteinuria,
glomerulosclerosis and ultimately renal fibrosis.
In ESRD, both uremia and dialysis can complicate blood glucose control by affecting the
secretion, clearance, and peripheral tissue sensitivity of insulin. The abnormal glucose
homeostasis in patients with dialysis is postulated to be multifactorial issues as Figure 1.
Figure 1. Contribution factors for the abnormal glucose metabolism in dialysis patients.
2.1. Hyperglycemia: Increased insulin resistance and decrease insulin production in dialysis
Advanced-stage chronic kidney disease (CKD) or ESRD can show mild fasting hyperglycemia
and abnormal glucose tolerance, suggesting that the uremic state alters glucose homeostasis
[14]. Insulin resistance is also frequently recognized in uremic patients and is a predictor of
cardiovascular mortality in ESRD patients [15]. Impaired insulin sensitivity in the absence of
overt diabetes play a central role in the development of atherosclerotic vascular disease [16].
Several clinical studies have noted impaired tissue sensitivity to insulin in diabetic nephrop‐
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athy [17], and non-diabetic patients exhibit only mild to moderate reductions in renal function
[18-20] and in ESRD [21, 22]. However, impaired insulin sensitivity in both dialysis groups
after long-term dialysis was still higher than that of the non-dialysis ESRD group while no
significant differences were noted between peritoneal dialysis and hemodialysis treatments
[23]. The mechanism of increased insulin resistance in patients with kidney disease is not fully
understood. Several factors, including uremic toxins, may increase insulin resistance in ESRD,
leading to a blunted ability to suppress hepatic gluconeogenesis and regulate peripheral
glucose utilization. In addition, in non-diabetic CKD patients, an independent factor for insulin
resistance was the amount of total body fat and body mass index [20]. This change occurs in
ESRD because of concomitant metabolic acidosis, deficiency of 1,25 dihydroxy-vitamin D, and
secondary hyperparathyroidism. In addition, in uremic patients, previous studies have
reported that treatment with hemodialysis, active vitamin D, erythropoietin and angiotensin
receptor blocker can improve insulin insensitivity [21, 24-26].
Further complicating the effect of dialysis is the glucose load provided by both dialysis
modalities. The dextrose concentration in the dialysate can also affect glucose control. In
hemodialysis population, dialysates with lower dextrose concentrations are used and may be
associated with hypoglycemia. Conversely, dialysates with higher dextrose concentrations are
occasionally used in hypoglycemic patients on hemodialysis and low ultrafiltration patients
on peritoneal dialysis (PD), but this can lead to hyperglycemia and insulin resistance [27].
2.2. Hypoglycemia: Decreased insulin clearance and renal gluconeogenesis in dialysis
Decreasing insulin requirements and frequent hypoglycemia also occur in diabetic patients on
dialysis. Renal insulin clearance decreases as glomerular filtration rate decreases to less than
15 to 20 mL/min/1.73 m2 [14]. Hepatic clearance of insulin is also decreased in patients with
uremia. In addition, deficient gluconeogenesis along with malnutrition, deficient catechola‐
mine release, and impaired renal insulin degradation and clearance, can contribute to frequent
hypoglycemia in patients with CKD [28, 29].
Thus, advanced CKD and ESRD on dialysis exert opposing forces on insulin secretion, action,
and metabolism, often creating unpredictable serum glucose values. Some patients who have
insulin resistance would need more supplemental insulin. In contrast, the reduced renal
gluconeogenesis and insulin clearance seen in ESRD may result in less requirement for insulin
treatment. Together, all of these factors contribute to wide fluctuations in plasma glucose levels
and increase the risk of both hyperglycemic and hypoglycemic events. Both of these abnor‐
malities are at least partially reversed with the institution of dialysis. As a result, the insulin
requirement in any given patient will depend upon the net balance between improving insulin
secretion and insulin sensitivity, and restoring normal hepatic insulin metabolism.
3. Glycemic control in dialysis
Glycemic therapy in patients with diabetes has been shown to improve outcomes, especially
microvascular complications in patients without kidney disease [30, 31]. The efficacy of
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glycemic control depends in part upon the stage at which it is begun and the degree of
normalization of glucose metabolism. Glycemic control can partially reverse the glomerular
hypertrophy and hyperfiltration that are thought to be important pathogenic pathways for
diabetic nephropathy, and decrease the incidence of new-onset microalbuminuria in retro‐
spective [32] and prospective studies of patients with diabetes [31, 33]. Progression of estab‐
lished overt nephropathy can also be stabilized or retarded through strict glycemic control.
However, proving the efficacy of this treatment is difficult, and previous studies examining
outcomes of glycemic control in dialysis patients gave conflicting results [34]. The benefit of
glucose control on progression in patients with CKD who have advanced kidney disease is
less well studied.
Interestingly, benefits of glycemic control after pancreas transplantation in patients with type
1 diabetes were observed: mesangial matrix volume, thickening of glomerular and tubular
basement membranes, and nodular glomerular lesions were significantly decreased and/or
returned to normal compared to the same measurements at zero and ten years [35, 36].
Effects of intensive glycemic control on prevention of macrovascular complications (e.g.,
coronary artery disease, peripheral artery disease, cerebrovascular disease) are less certain,
particularly in type 2 diabetes. The 10-year follow-up study of patients with type 2 diabetes in
the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated risk reduction for
myocardial infarction and death from any cause [37]. More recent studies, including the Action
to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and the Veterans
Affairs Diabetes Trial (VA-DT) that targeted even lower hemoglobin A1c (HbA1c) goals (<6–
6.5%), failed to show cardiovascular disease risk reduction with more intensive glycemic
control regimens [38-40].
Several observational studies showed that higher levels of hemoglobin A1c were associated
with higher mortality rates in patients with diabetes on long-term dialysis and CKD [41-44].
A previous study demonstrated that a paradoxically lower unadjusted mortality associated
with greater hemoglobin A1c levels were found in 23,618 dialysis patients with diabetes.
However, after adjusting for markers of malnutrition and inflammation, hemodialysis patients
with hemoglobin A1c levels <5% or >7% became associated with greater mortality [45]. The data
indicate that competing risk factors related to malnutrition, muscle wasting, and anemia may
confound the association between glycemic control and survival in diabetic patients with long-
term dialysis. In the study by Williams, hemoglobin A1c levels >11.0% in type 1 diabetes on
hemodialysis were required to observe a statistically significant higher mortality risk, but few
subjects had hemoglobin A1c levels in this category [46]. In a recent cohort of 54,757 diabetic
hemodialysis patients, poor glycemic control (hemoglobin A1c ≥8% or serum glucose ≥200 mg/
dL) appears to be associated with high all-cause and cardiovascular death and very low
glycemic levels (hemoglobin A1c <7%) are also associated with high mortality risk [47]. In a
single interventional study in 83 dialysis patients, patients in the intensive intervention group
experienced improved quality of life and a decreased need for amputations and hospitaliza‐
tions [48]. Larger clinical trials are needed to conclusively prove the concept that better
glycemic control is beneficial in patients with advanced CKD. To date, there are no data
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
157
available from randomized clinical trials targeting different hemoglobin A1c levels and
powered for cardiovascular events or mortality in ESRD populations. Careful evaluation of
the relationship of hemoglobin A1c with these outcomes in ESRD patients should be a high
priority for future research to determine the risks and benefits of different hemoglobin A1c
targets.
The Kidney Disease Outcomes Quality Initiative (KDOQI) foundation state that target
hemoglobin A1c for people with diabetes should be <7%, irrespective of presence or absence
of CKD. This recommendation is in line with diabetes management in the general population
[11]. However, very few studies have addressed the benefits and risks of intensive glycemic
control in late stages of CKD and ESRD. Recent evidence from randomized studies has
highlighted the potential risks of aggressive glycemic control in non-ESRD diabetic popula‐
tions [38, 39]. Moreover, because many dialysis patients are wasting, malnourished, and non-
ambulatory, they may be less able to respond appropriately to hypoglycemia. Current
evidence suggests that aggressive glycemic control cannot be routinely recommended for all
diabetic hemodialysis patients on the basis of reducing mortality risk. Physicians are encour‐
aged to individualize glycemic targets based on potential risks and benefits in diabetic ESRD
patients.
The guidelines of the 2012 American Diabetes Association recommend lowering hemoglobin
A1c to below or around 7% for many adults, and to implement this soon after the diagnosis of
diabetes that is associated with long-term reduction in macrovascular disease [49]. Providers
might reasonably suggest more stringent hemoglobin A1c goals (such as <6.5%) for selected
individual patients, if this can be achieved without significant hypoglycemia or other adverse
effects of treatment. Appropriate patients might include those with short duration of diabetes,
long life-expectancy, and no significant cardiovascular disease. Less stringent hemoglobin
A1c goals (such as <8%) may be appropriate for patients with a history of severe hypoglycemia,
limited life- expectancy, advanced microvascular or macrovascular complications, extensive
comorbid conditions, and those with longstanding diabetes in whom the general goal is
difficult to attain [49]. Therefore, providers should be vigilant in preventing severe hypogly‐
cemia in patients with advanced kidney disease or ESRD and should not aggressively attempt
to achieve near-normal hemoglobin A1c levels in patients in whom such a target cannot be
reasonably easily and safely achieved.
4. Monitoring of glycemia in dialysis
Glucose homeostasis is altered significantly in patients with uremia. Glycated hemoglobin
(expressed as a percentage of total hemoglobin) or hemoglobin A1c measurement is used as an
indicator of integrated glucose control. Glycated hemoglobin is formed by the non-enzymatic
reaction between glucose and the N-terminal amino group on the beta chain of hemoglobin.
The good correlation between hemoglobin A1c and blood glucose in non-CKD type 1 diabetic
patients has been documented in the Diabetes Control and Complications Trial (DCCT) [50].
At present, this test is the most accurate method to assess chronic glycemic control based on
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clinical outcomes associated with certain hemoglobin A1c levels in diabetic patients with
normal kidney function [31]. The validity of glycated hemoglobin and hemoglobin A1c has not
been rigorously studied in patients with ESRD. These tests may be unreliable in dialysis
patients because of assay interference due to the elevated blood urea nitrogen. Glycated
hemoglobin tests, such as column- and ion-exchange chromatography and agar gel electro‐
phoresis, are affected by uremia. This is due in part to analytical interference from carbamy‐
lated hemoglobin formed in the presence of elevated concentrations of urea, leading to false
elevations in the hemoglobin A1c level. Use of agarose affinity chromatography or the thio‐
barbituric acid method for analyzing hemoglobin A1c can be used reliably in patients with
ESRD. Other factors such as shorter life span of red blood cells, iron deficiency anemia, and
recent transfusion may also cause underestimation of glucose control in diabetic hemodialysis
patients (Table 1). In addition, patients treated with erythropoietin could lead to underesti‐
mation of glycemic control by using hemoglobin A1c level, because of the greater proportion
of young erythrocytes in the circulation of patients [51]. Therefore, hemoglobin A1c levels tend
to underestimate glycemic control in diabetic patients undergoing long-term maintenance
hemodialysis [52, 53].
Falsely increased hemoglobin A1c Falsely decreased hemoglobin A1c
Carbamylated hemoglobin for charge-dependent
chromatography assays
Erythropoiesis supplement
Increased glycosylation rate Shortened life span of red blood cells
Uremia Blood transfusions
Metabolic acidosis Hemoglobinopathy
Table 1. Glycated hemoglobin levels in dialysis patients
Despite anemia and shortened RBC lifespan in ESRD patients, hemoglobin A1c in the range of
6% to 7% estimates glycemic control similarly to patients without severe renal impairment.
Hemoglobin A1c above 7.5% may overestimate hyperglycemia in patients with ESRD [43]. It
is important to be aware of the specific assay used and the other factors affecting the accuracy
of hemoglobin A1c measurements in ESRD on hemodialysis and peritoneal dialysis.
Another potential method to monitor glycemic control in patients with uremia is glycated
albumin. Some studies suggest that glycated albumin more accurately reflects glycemic control
in diabetic hemodialysis patients than hemoglobin A1c [54, 55]. However, falsely increased
glycated albumin values have been measured in the presence of lipemia, hemolysis, and high
bilirubin and uric acid concentrations. In addition, use of glycated albumin is hampered by
conditions that alter protein metabolism including ESRD, their lack of availability in routine
practice and the lack of established reference levels [56].
Despite the limitations in using hemoglobin A1c in the dialysis population, this test is consid‐
ered a reasonable measure of chronic glycemic control in this group. Patient self-monitoring
of blood glucose is also available for patients to assess the effectiveness of the management
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plan on glycemic control. It provides real-time assessments of glycemic control and results of
self-monitoring of blood glucose can be useful in preventing hypoglycemia and adjusting
medications (particularly prandial insulin doses), and physical activity. There are some
limitations of this method, because it is subject to errors from poor technique, problems with
the meters and strips, and lower sensitivity in measuring low blood glucose levels. However,
hemoglobin A1c does not provide a measure of glycemic variability or hypoglycemia. Thus,
for patients prone to glycemic variability (especially type 1 patients, or type 2 patients with
severe insulin deficiency), glycemic control is best judged by the combination of results of self-
monitoring of blood glucose testing and the hemoglobin A1c assay [49]. Hemoglobin A1c may
also serve as a check for the accuracy of the patient’s meter and the adequacy of the self-
monitoring schedule of blood glucose testing.
5. Insulin therapy in dialysis
Insulin regulates glucose homeostasis at many sites, reducing hepatic glucose output by
decreasing gluconeogenesis and glycogenolysis, and increasing the rate of glucose uptake,
primarily into muscle and adipose tissue. Insulin affects cells through binding to its receptor
on the surface of insulin-responsive cells. The stimulated insulin receptor phosphorylates
itself, and several substrates including membranes of the insulin receptor substrate family and
initiate downstream signaling events [27].
In healthy non-diabetic people, the pancreatic β-cells secrete half of the daily insulin require‐
ment (approximately 0.5 units/kilogram/day) at a steady basal rate independent of glucose
levels and the other half is secreted in response to prandial glucose stimulation [57]. Insulin is
secreted into the portal system, it passes through the liver where approximately 75% is
metabolized with the remaining 25% metabolized by the kidneys. About 60% of the insulin in
the arterial bed is filtered by the glomerulus and 40% is actively secreted into the nephric
tubules [58]. Most of the insulin in the tubules is metabolized into amino acids, and only 1%
of insulin is secreted intact.
Interestingly, endogenous insulin is substantially degraded by the liver but exogenous insulin
is eliminated mainly by the kidney. For diabetic patients receiving exogenous insulin, renal
metabolism plays a more significant role since there is no first-pass metabolism in the liver.
Insulin is freely filtered at the glomerulus and extensively reabsorbed in the proximal tubule
after enzyme degradation into smaller peptides. As renal function starts to decline, insulin
clearance does not change appreciably, due to compensatory peritubular insulin uptake [59].
However, once the glomerular filtration rate drops below 20 mL/min, insulin clearance
decreases and the half-life of insulin increases, an effect compounded by a decrease in the
hepatic metabolism of insulin that occurs in uremia [25]. Glucose and insulin homeostasis are
altered in CKD patients even in the early stages of CKD, leading to insulin resistance by various
pathways. Studies even in the 1980s showed that, although insulin secretion in CKD is normal,
a decreased tissue sensitivity to insulin is responsible for the abnormal glucose uptake [60]. In
advanced CKD, particularly in stages 4 and 5, significant metabolic derangements in insulin
Hemodialysis160
metabolism occur. Several factors have been implicated in the pathogenesis of insulin resist‐
ance including anemia, dyslipidemia, uremia, malnutrition, excess of parathyroid hormone,
vitamin D deficiency, metabolic acidosis, and increase in plasma free fatty acids and proin‐
flammatory cytokines. Thus, despite the increase in insulin resistance caused by renal failure,
the net effect is a reduced requirement for exogenous insulin in ESRD patients [61]. Despite
similar duration of disease and clinical characteristics, patients with type 2 diabetes with ESRD
often show marked heterogeneity in terms of insulin requirement and dosages [62]. However,
predictors for exogenous insulin requirement in patients with type 2 diabetes undergoing
continuous ambulatory peritoneal dialysis (CAPD) have not been defined. Possible factors
include β-cell function, endogenous metabolism and elimination of insulin, insulin resistance,
body size, carbohydrate intake, and extra glucose absorbed from dialysate fluid [27].
Recent evidence showed that insulin is a anti-inflammatory hormone that suppresses several
proinflammatory transcription factors such as nuclear factor κB (NF-κB), early growth
response protein 1 and activating protein 1, which all mediate inflammation. An impairment
of the action of insulin because of insulin resistance would therefore result in the activation of
these proinflammatory transcription factors and in an increase of the expression of the
corresponding genes. Derangements in other biologic effects of insulin could be associated
with certain pathologic states in CKD such as hypertension and insulin resistance [63, 64].
Previous studies have shown that uremia was associated with an insulin-resistant state, mainly
because of decreased insulin-stimulated uptake of glucose by muscle [65]. However, in clinical
practice, with progressive renal failure, the insulin requirements of patients with diabetes for
glycemic control often tend to decrease [66]. The determinants of insulin requirements in
patients with diabetes with ESRD remain uncertain. This can be influenced by factors such as
insulin resistance, production and metabolism of endogenous insulin, oral intake, extra
carbohydrate absorbed from dialysis solution, and reduction of body weight in uremic patients
[27, 67]. Possible factors for this reduction in insulin requirement include reduced renal
clearance of both endogenous and exogenous insulin and progressive loss of appetite and body
weight in uremic patients. However, several studies have shown similar fasting insulin levels
between patients with renal failure and those with normal renal function [27, 68].
In PD patients, the development of insulin resistance after a initial improvement is generally
attributed to a high glucose load absorbed from dialysis fluid, contributing to a wide spectrum
of metabolic abnormalities including hypertriglyceridemia, poor glycemic control, new-onset
diabetes, hypertension and central obesity. An amplifying loop in the process of glucose
absorption appears to be a consequence of the modifications in the peritoneum associated with
a loss of ultrafiltration capacity [69]. Disturbances of carbohydrate metabolism seem to be even
more intense in non-diabetic PD patients than in hemodialysis patients. After PD initiation, a
large number of patients developed new-onset hyperglycemia because of their exposure to
hypertonic glucose solutions [27, 70, 71]. In fact, glucose absorption through the peritoneum
results in significantly higher serum glucose levels than are produced by an equivalent dose
of oral dextrose. Wong et al. show considerable variations in the need for insulin treatment
and dosages in patients with type 2 diabetes undergoing CAPD despite similar disease
duration, dialysis regimens, renal function, and glycemic control [67]. Duration of diabetes,
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hemoglobin A1c level, and body weight were independent determinants of insulin requirement
of patients with type 2 diabetes with ESRD patients undergoing CAPD. Dialysis regimen with
estimated amount of glucose absorbed and Kt/V did not predict insulin requirement in these
patients. Insulin resistance, insulin requirement, and fasting C-peptide levels, a crude meas‐
urement of basal pancreatic β-cell function in patients with diabetes with normal renal
function, were not affected by dialysis dosage, reflected by a similar value of Kt/V [67]. Insulin-
treated patients had lower C peptide concentrations than non-insulin-treated patients, and
insulin dosage required was correlated with duration of diabetes mellitus, implying the
significance of β-cell function in determination of insulin requirement in patients with type 2
diabetes with ESRD.
Insulin injection therapy remains the mainstay treatment to achieve good glycemic control in
diabetic patients receiving hemodialysis therapy [72]. In hemodialysis patients, the insulin
sensitivity normally improves on both an acute and chronic basis [66], mainly by clearing
circulating urea, and also insulin clearance. The concentration of glucose and insulin is
frequently affected by the dialysis procedure itself. Changes in glucose will vary with the
concentration of glucose (dextrose) in the dialysis fluid, to which the patient’s blood is
indirectly exposed. Because glucose transfers to the dialysate according to its concentration
gradient, dialysate lacking glucose is associated with significant decreases in plasma glucose
levels in poorly and well-controlled diabetic patients as well as in some non-diabetic patients,
and is no longer used. Plasma insulin levels also are decreased during the hemodialysis
treatment, due to clearance by dialysis which varies among membranes and with the fall in
glucose. Additional metabolic effects of dialysis include improvement in sensitivity to insulin
and decrease in some cases of counter-regulatory hormones (e.g., growth hormone). In poorly
controlled patients, hemodialysis-induced clearance of plasma immunoreactive insulin levels
may result in hyperglycemia in the post-dialysis period [63].
Various insulin preparations are available in the market. In ESRD patients, insulin doses will
need to be reduced, especially after dialysis has been initiated [63]. Sobngwi et al. show that
the daily insulin needs on the day after hemodialysis should be decreased approximately 15%
compared with the daily insulin needs before hemodialysis, with a significant reduction of
basal hourly insulin requirement by 25%, unchanged boluses, and unchanged body weight-
indexed total insulin dose in a group of type 2 diabetic patients on maintenance hemodialysis
[73]. However, no evidence for the benefit of neutral protamine hagedorn (NPH) insulin or
other long-acting insulin in patients with ESRD is available. On the other hand, insulin lispro
which has a short onset of action and a short duration of action shows the benefit not only
facilitate the correction of hyperglycemia but may also decrease the risk of late hypoglycemic
episodes, which is of increased relevance in hemodialysis patients [64] because its pharmaco‐
kinetics is less affected in renal failure [74]. Long-acting insulin such as insulin glargine or NPH
insulin can be widely used as basal requirements, along with a rapid-acting insulin analogue
such as lispro or insulin aspart before meals two or three times daily [57]. When the glomerular
filtration rate drops between 10 and 50 mL/min, the total insulin dose should be reduced by
25%. Once the filtration rate is below 10 mL/min, as in ESRD patients, the insulin dose should
be decreased by 50% from the previous amount [75].
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Unexpected hypoglycemia often occurs in dialysis patients during basal-bolus insulin therapy
despite careful adjustment of their insulin dose which may due to 3 main factors: (1) prolon‐
gation of the elimination half-life of insulin associated with decreased renal degradation and
excretion [68]; (2) impairment of gluconeogenesis by the kidneys and (3) weak gastric peri‐
stalsis in diabetic patients on dialysis, with prolongation of stomach food retention, resulting
in delays in glucose absorption [76]. It is important to note that the signs and symptoms of
hyperglycemia are modified in patients with ESRD [63]. Signs and symptoms of hyperglyce‐
mia may involve thirst, fluid overload, and hyperkalemia rather than polyuria. Lacking
polyuria, patients experience volume expansion, not contraction; excessive thirst will result in
large weight gains, which correlate with poor glycemic control between dialysis treatments.
Severe hyperglycemia may result in hyperkalemia and complicate management further. Other
findings may be pulmonary edema, hypertension, anorexia, altered mental status, nausea,
vomiting, and gastroparesis, although symptoms are frequently nonspecific or lacking.
6. Oral antihyperglycemic drugs in dialysis
Therapeutic options for patients with diabetes with CKD and ESRD are limited because a
reduced glomerular filtration rate results in the accumulation of certain drugs and/or their
metabolism [77]. Most of oral antihyperglycemic drugs include the insulin secretagogues such
as sulfonylureas and meglitinides, biguanides, thiazolidinediones, and alpha-glucosidase
inhibitors are contraindicated in ESRD patients. However, some agents have been used in
patients with CKD and were found to be effective and safe even in those on dialysis. Therefore,
some medications may be useful therapeutic options for the management of diabetes in CKD.
As shown in Table 2, insulin secretagogues can be classified as sulfonylureas and meglitinides
while alpha-glucosidase inhibitors are modifiers of glucose absorption and thiazolidinediones
are insulin sensitizers. Incretin-related therapies include dipeptidylpeptidase-4 (DPP-4)
inhibitors and incretin mimetics. DPP-4 inhibitors are oral antidiabetic agents, whereas incretin
mimetics are used by subcutaneous injection.
Since many drugs bind to serum protein, primarily albumin and plasma concentration of
albumin in patients with renal impairment is commonly decreased, the concentrations of
unbound drugs are increased.
Sulfonylureas
Insulin secretagogues increase endogenous insulin levels. These agents work by binding to
sulfonylurea receptors or nearby sites, resulting in closure of ATP-sensitive potassium
channels of the pancreatic β-cell, depolarization of the cell membranes, calcium influx, and
subsequently insulin release [72]. They have a wide volume of distribution and are highly
protein-bound. However, only the unbound drug exerts a clinical effect. Because of high
protein binding property, dialysis cannot effectively clear elevated levels of sulfonylurea
drugs. As these agents increase endogenous insulin levels, they are associated with an
increased risk of hypoglycemia. This risk is mitigated when shorter-acting agents are used.
Furthermore, many ESRD patients take drugs such as sulfonamides, vitamin K antagonists,
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beta-blocker, salicylates and fibric acid derivatives which may displace sulfonylureas from
albumin, thus increasing the risk of severe hypoglycemia.
Category Action Group Medication Medication Medication 
Dosing recommendation CKD stage 3, 4 or 
kidney transplant 
Dialysis dose recommendation
Insulin Sensitizers Biguanides Metformin 
  
Contraindicated with kidney dysfunction defined 
as sCr³1.5 mg/dL in men or³1.4 mg/dL in women 
Avoid 
Insulin Sensitizers TZDs (PPAR) Pioglitazone No dose adjustment needed No dose adjustment needed 
Insulin Sensitizers TZDs (PPAR) Rivoglitazone No dose adjustment needed No dose adjustment needed 
Insulin Sensitizers TZDs (PPAR) Rosiglitazone No dose adjustment needed No dose adjustment needed 
Insulin Sensitizers Dual PPAR agonist Aleglitazar Use with caution Use with caution 
Insulin Sensitizers Dual PPAR agonist Muraglitazar Use with caution Use with caution 
Insulin Sensitizers Dual PPAR agonist Tesaglitazar Use with caution Use with caution 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Acetohexamide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Carbutamide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Chlorpropamide 
Reduce dose by 50% when  
GFR<70 and 50³mL/min/1.73m2 and avoid 
 when GFR<50 mL/min/1.73 m2 
Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Metahexamide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Tolbutamide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 1st generation Tolazamide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 2nd generation Glipizide Preferred, no dose adjustment needed 
Preferred, no dose adjustment 
needed 
Insulin Secretagogues K+ ATP Sulfonylureas 2nd generation Gliclazide Preferred, no dose adjustment needed 
Preferred, no dose adjustment 
needed 
Insulin Secretagogues K+ ATP Sulfonylureas 2nd generation Glyburide Avoid Avoid 
Insulin Secretagogues K+ ATP Sulfonylureas 2nd generation Glimepiride Initiate at low dose, 1 mg daily Avoid 
Insulin Secretagogues K+ ATP Meglitinides Nateglinide Initiate at low dose, 60 mg before each meal Avoid 
Insulin Secretagogues K+ ATP Meglitinides Repaglinide 
 
No dose adjustment needed, initiate at 0.5 mg 
dose when GFR<40 mL/min/1.73 m2 
No dose adjustment needed 
Insulin Secretagogues K+ ATP Meglitinides Mitiglinide No dose adjustment needed No dose adjustment needed 
Insulin Secretagogues 
GLP-1 analogs 
(Incretin Mimetics) 
Exenatide 
  
Not recommended in patients with  
GFR<30 mL/min/1.73 m2 and caution should be 
applied when GFR>30 and< 50 mL/min/1.73 m2, 
No dose adjustment needed when GFR>50 and 
<80 mL/min/1.73 m2 
Avoid 
Insulin Secretagogues 
GLP-1 analogs 
(Incretin Mimetics) 
Liraglutide 
  
No dose adjustment needed No dose adjustment needed 
Insulin Secretagogues DPP-4 inhibitors Alogliptin 
  
Reduce dose by 50% (12.5 mg/day) when GFR<50 
and 30 ³ mL/min/1.73 m2 and by 75% (6.25 
mg/day) when GFR<30 mL/min/1.73 m2 
Reduce dose by 75%  
(6.25 mg/day) 
Insulin Secretagogues DPP-4 inhibitors Linagliptin No dose adjustment needed No dose adjustment needed 
Insulin Secretagogues DPP-4 inhibitors Sexagliptin 
  
Moderate to severe kidney impairment should 
receive<2.5 mg/d 
Moderate to severe kidney 
impairment should  
receive<2.5 mg/d 
Insulin Secretagogues DPP-4 inhibitors Sitagliptin 
  
Reduce dose by 50% (50 mg/day) when GFR<50 
and 30³mL/min/1.73 m2 and by 75% (25 mg/day) 
when GFR<30 mL/min/1.73 m2 
Reduce dose by 75% (25 mg/d) 
Insulin Secretagogues DPP-4 inhibitors Vildagliptin Initiate at low dose Initiate at low dose 
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Category Action Group Medication Medication Medication 
Dosing recommendation CKD stage 3, 4 or 
kidney transplant 
Dialysis dose recommendation
Insulin 
Analogs/other 
insulins 
Rapid-acting Regular 
  
Preferred, normally no dose adjustment needed 
Preferred, normally no dose 
adjustment needed but depends 
on dialysis factors as well 
Insulin 
Analogs/other 
insulins 
Rapid-acting Lispro 
  
Preferred, normally no dose adjustment needed 
Preferred, normally no dose 
adjustment needed but depends 
on dialysis factors as well 
Insulin 
Analogs/other 
insulins 
Rapid-acting Aspart 
  
Preferred, normally no dose adjustment needed 
Preferred, normally no dose 
adjustment needed but depends 
on dialysis factors as well 
Insulin 
Analogs/other 
insulins 
Long-acting NPH 
  
Dose adjustment needed depends on  
individual factors 
Reduce dose by 25% when GFR 
10-50 mL/min and by 50% when 
GFR<10 mL/min 
Insulin 
Analogs/other 
insulins 
Long-acting Glargine 
  
Dose adjustment needed depends on  
individual factors 
Reduce dose by 25% when GFR 
10-50 mL/min and by 50% when 
GFR<10 mL/min 
Insulin 
Analogs/other 
insulins 
Long-acting Determir 
  
Dose adjustment needed depends on  
individual factors 
Reduce dose by 25% when GFR 
10-50 mL/min and by 50% when 
GFR<10 mL/min 
Insulin 
Analogs/other 
insulins 
Premixed 
70/30 human 
mix   
Dose adjustment needed depends on 
 individual factors 
Dose adjustment needed 
depends on individual factors 
Insulin 
Analogs/other 
insulins 
Premixed 70/30 aspart mix
  
Dose adjustment needed depends on 
 individual factors 
Dose adjustment needed 
depends on individual factors 
Insulin 
Analogs/other 
insulins 
Premixed 75/25 lispro mix
  
Dose adjustment needed depends on 
 individual factors 
Dose adjustment needed 
depends on individual factors 
Others 
Alpha-
glucosidase 
inhibitor 
 
Acarbose 
  
Not recommended in patients with sCr>2 mg/dL Avoid 
Others 
Alpha-
glucosidase 
inhibitor 
 
Miglitol 
  
Not recommended in patients with sCr>2 mg/dL Avoid 
Others 
Alpha-
glucosidase 
inhibitor 
 
Vogibose 
  
Not recommended in patients with sCr>2 mg/dL Avoid 
Others Amylin analog 
 
Pramlintide 
  
No dose adjustment needed for  
GFR 20-50 mL/min/1.73 m2 
No data available 
Others SGLT2 inhibitor Canagliflozin No data available No data available 
* Modify from Masanori Abe, Kazuyoshi Okada and Masayoshi Soma "Antidiabetic agents in patients with chronic kidney
disease and end-stage renal disease on dialysis: metabolism and clinical practice" Current Drug Metabolsim Volume 12,
January 2011, with permission.
Table 2. Oral anti-diabetic drugs and insulin analogs
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The first-generation sulfonylureas-chlorpropamide, acetohexamide, tolbutamide, and tolaza‐
mide are almost exclusively excreted by the kidney and are therefore contraindicated in ESRD
patients [78]. Second-generation agents include glimepiride and glyburide which are metab‐
olized in the liver. However, their active metabolites are excreted in the urine and so these
medications should be avoided in ESRD patients as well [72] but low-dose initiation can be
used in patients with CKD [79]. Glipizide and gliclazide are the preferred agents and no dose
adjustment has been necessary in a dialysis population [11].
Most sulfonylureas are not suitable for ESRD patients due to the risk of prolonged hypogly‐
cemic; furthermore, metformin is contraindicated [80]. From all medications in this group, the
only sulfonylurea recommended in ESRD patients are glipizide and gliclazide which are also
metabolized in the liver but has inactive or weakly active metabolites excreted in the urine [57].
Glipizide is eliminated primarily by hepatic biotransformation; < 10% of a dose is excreted as
unchanged drug in urine or feces while approximately 90% is excreted as biotransformation
products in urine (80%) and feces (10%). The major metabolites of glipizide are products of
aromatic hydroxylation that have no hypoglycemic activity. A minor metabolite which
accounts for < 2% of a dose, an acetylamino-ethyl benzene derivative, is reported to have 1/10
to 1/3 of the hypoglycemic activity compared to the parent compound. The suggested dose of
glipizide is 2.5 to 10 mg/day. In ESRD patients, sustained-release forms should be avoids due
to the concerns of hypoglycemia [81].
Meglitinides
Repaglinide, nateglinide and mitiglinide are insulin secretagogues that stimulate pancreat‐
ic β-cells.  They are currently in clinical use because of their rapid onset of action result‐
ing  in  improvement  in  hyperglycemia.  Like  sulfonylureas,  nateglinide  is  hepatically
metabolized, with renal excretion of active metabolites. On the other hand, repaglinide is
almost  completely  converted  to  inactive  metabolites  in  the  liver,  and  less  than  10%  is
excreted by the kidneys [82, 83]. Nateglinide still pose a risk of hypoglycemia especially in
ESRD  patients.  Because  of  that,  this  drug  is  not  recommended  to  use  in  patients  on
hemodialysis  [82,  83].  However,  mitiglinide shows selective  action on the ATP-sensitive
potassium channel of pancreatic β-cells and the order of affinity is mitiglinide > repagli‐
nide > nateglinide [84].  This result suggests that mitiglinide induces insulin secretion by
specifically acting on pancreatic β-cells and has few unwanted effects on the cardiovascu‐
lar  system.  Because  mitiglinide  is  rarely  accompanied  by  hypoglycemia,  it  may  be  an
attractive therapeutic option for patients undergoing dialysis [85].  However,  the optimal
daily dose of mitiglinide is suggested to be lower in the diabetic hemodialysis patients than
that in the diabetic patients with normal kidney function. Mitiglinide has the potential to
reduce  the  number  of  type  2  diabetics  on  hemodialysis  who  ultimately  require  insulin
injection therapy. The daily dose of mitiglinide (23 mg) was adequate, as evidenced by the
fact that it was able to induce significant reductions in glycemic parameters such as fasting
plasma glucose, hemoglobin A1c, glycated albumin, and homeostasis model assessment for
insulin resistance (HOMA-IR) levels [86]. This suggests that appropriate blood glucose levels
can be  maintained even at  a  low dose  of  mitiglinide,  not  only  during the  postprandial
period but also before meals, due to the prolonged half-life of mitiglinide in patients on
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dialysis compared with the half-life in those with normal renal function. Abe et al. reported
that mitiglinide significantly improved glycemic control, triglyceride levels and interdialyt‐
ic weight gain even when administered for only a short duration [87].  Thus, mitiglinide
not only improved hemoglobin A1c  and glycated albumin,  the overall  index of glycemic
control in type 2 diabetes, but also effectively improved fasting plasma glucose in dialy‐
sis patients [72, 85].
Biguanides
Metformin, the drug of choice for many patients with type 2 diabetics, is a biguanide that
reduces hepatic gluconeogenesis and glucose output. Metformin does not cause increase
insulin levels, but rather decreases hepatic glucose output by suppressing fasting gluconeo‐
genesis. It is absorbed via the small intestine and the absolute bioavailability is approximately
50-60%. Intravenous single-dose studies in normal subjects demonstrate that metformin is
excreted unchanged in the urine and does not undergo hepatic metabolism or biliary excretion
[88]. Renal clearance of metformin is approximately 3.5-fold greater than creatinine clearance,
which indicates that tubular secretion via human organic cation transporter 2 is the major route
of metformin elimination [89]. Single-dose and steady-state pharmacokinetics of metformin
were compared between patients with normal renal function (CrCl > 90 mL/min), mild
impaired renal function (CrCl 61-90 mL/min) as well as moderate (CrCl 31-60 mL/min) and
severe impaired renal function (CrCl 10-30 mL/min). The results show that in patients with
moderate to severe impaired renal function, Cmax and AUC are increased 173% and 390%,
respectively, compared to the patients with normal renal function [89]. In patients with
decreased renal function, based on the measurement of CrCl, the plasma half-life of metformin
is prolonged and renal clearance is decreased in proportion to the decrease in CrCl [89].
Therefore, metformin should be avoided in patients with moderate to severe CKD including
those on dialysis since the risk of metformin accumulation and lactic acidosis increases in line
with the degree of impairment of renal function [90].
Thiazolidinediones
Rosiglitazone and pioglitazone are highly potent, selective agonists that work by binding to
and activating a nuclear transcription factor, specifically, peroxisome proliferator-activated
receptor gamma (PPAR-gamma) which improves insulin resistance in type 2 diabetic patients
[91, 92] as well as increase glucose uptake in muscles and adipose tissue, and decrease hepatic
glucose production [92, 93]. Both rosiglitazone and pioglitazone have an adequate oral
bioavailability and are extensively metabolized by the liver. Rosiglitazone is mainly metabo‐
lized by CYP2C8 into inactive metabolites and < 1% of the parent drug appears in the urine in
unchanged form [80, 94]. The half-life of rosiglitazone is similar in patients with ESRD and in
healthy individuals, and can therefore be administered to ESRD patients without dose
adjustment or risk of causing hypoglycemia [95-97]. Pioglitazone is metabolized by CYP3A4
and CYP2C8/9 [98]. Metabolites of pioglitazone are more active than those of rosiglitazone and
are excreted predominantly in bile. The pioglitazone metabolites do not accumulate in CKD.
The pharmacokinetics profile of pioglitazone was found to be similar in healthy subjects and
patients with moderately or severely impaired renal function who did not require dialysis [98].
Moreover, in patients who did require dialysis, pioglitazone was found to have a Tmax of 1.8 h
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
167
and a half-life of 5.4 h [98]. Therefore, a post-dialysis supplementary dose is not required, and
pioglitazone can be administered irrespective of the time of dialysis. Due to the high molecular
weight (392 Da), high protein-binding capacity (> 98%) and predominant hepatic metabolism
of pioglitazone, its pharmacokinetics is similar in patients with normal renal function and
CKD, and in those undergoing dialysis therapy. The main adverse reaction of these agents is
edema, especially when they are used in combination with insulin. Because of that, a joint
statement of the American Diabetes Association and the American Heart Association recom‐
mends avoiding thiazolidinediones in patients in New York Heart Association class III or IV
heart failure [99]. Moreover, caution is required in patients in compensated heart failure (New
York Heart Association class I or II) or in those at risk of heart failure such as patients with
history of myocardial infarction or angina, hypertension, left ventricular hypertrophy,
significant aortic or mitral value disease, age greater than 70 years, or diabetes for more than
10 years [99].
Thiazolidinediones have been reported to (1) reduce insulin requirements, (2) ameliorate
albuminuria (3) have various roles in lipid metabolism, fibrinolysis, platelet aggregation and
coagulation, (4) protect against impairment of endothelial function and (5) have an anti-
inflammatory effect [100-103]. When used for the clinical management of type 2 diabetes and
ESRD, thiazolidinediones are primarily metabolized in the liver and will not accumulate in
patients with CKD. They might also improve uremia-associated insulin resistance and confer
benefits at the metabolic, inflammatory, vascular, and hemodynamic levels [100]. The efficacy
of this drug in patients with normal renal function is similar to the efficacy in those with mild
to moderate renal impairment [104]. Administration of pioglitazone is also associated with
mean decreases in triglyceride levels and mean increases in high-density lipoprotein (HDL)-
cholesterol without consistent changes in the mean levels of total cholesterol or low-density
lipoprotein (LDL)-cholesterol in non-uremic patients [105].
Thiazolidinediones are known to reduce HOMA-IR and levels of high-sensitivity C-reactive
protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α), and increase adiponectin levels in
patients not undergoing dialysis [72]. In patients undergoing PD, thiazolidinediones have been
reported to reduce hs-CRP levels, but levels of interleukin-6 (IL-6) and TNF-α were not reduced
[91, 102]. In a short-term study of dialysis patients, thiazolidinediones are reported to reduce
the levels of hs-CRP but not adiponectin [106]. It has been reported that pioglitazone treatment
reduced the levels of hs-CRP, IL-6 and TNF-α and increased the high-molecular weight
adiponectin level even in hemodialysis patients [107]. Moreover, the dosage of erythropoiesis-
stimulating agents was significantly reduced during pioglitazone treatment with improve‐
ment in insulin resistance and a decrease in the levels of inflammatory cytokines [107].
It can be concluded that even though ESRD and dialysis do not affect the metabolism of
thiazolidinediones, the medications in this group are not recommended in ESRD patients due
to the associated risk of fluid accumulation and precipitation of heart failure.
Alpha-glucosidase inhibitors
Enzyme alpha-glucosidase is located in the gut and hydrolyzed oligosaccharides, trisacchar‐
ides and disaccharides into glucose in the brush border of the small intestine. The antihyper‐
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glycemic action of alpha-glucosidase inhibitors results from the reversible inhibition of
membrane-bound intestinal alpha-glucoside hydrolase enzymes. Alpha-glucosidase inhibi‐
tors decrease the rate of breakdown of complex carbohydrates so that less glucose is absorbed
and postprandial hyperglycemia is lowered but they do not enhance insulin secretion. The
main side effects are gastrointestinal including flatulence and diarrhea.
Acarbose and miglitol slow carbohydrate absorption from the intestine. The levels of these
drugs and their active metabolites are higher in patients with renal failure [80], and since data
are scarce on the use of these drugs in ESRD, they are contraindicated in ESRD patients [11].
Acarbose is  metabolized by intestinal  bacteria and digestive enzymes exclusively within
the gastrointestinal tract. Within 96 h of ingestion, 51% of an oral dose was excreted in the
faces and unabsorbed drug-related radioactivity. Because acarbose acts locally within the
gastrointestinal tract, low systemic bioavailability of the parent compound is therapeutical‐
ly  desirable.  A fraction of  these  metabolites  (about  34% of  the dose)  was absorbed and
subsequently excreted in urine. The major metabolites have been identified as 4-methylpyr‐
ogallol  derivatives (such as sulfate,  methyl,  and glucuronide conjugates).  Moreover,  one
metabolite  (formed  by  cleavage  of  a  glucose  molecule  from  acarbose)  also  has  alpha-
glucosidase  inhibitory  activity.  This  metabolite,  together  with  the  parent  compound,
recovered from the urine, accounts for < 2% of the total administered dose. Although < 2%
of  an  oral  dose  of  acarbose  was  absorbed  as  active  drug,  patients  with  severe  renal
impairment  (CrCl  <  25  mL/min)  attained increases  about  5-fold higher  for  peak plasma
concentration of acarbose and 6-fold higher for AUC values than subjects with normal renal
function [108].  Because long-term clinical trials in diabetic patients with significant renal
dysfunction  have  not  been  conducted,  treatment  of  these  patients  with  acarbose  is  not
recommended [108].
Miglitol is not metabolized in humans or other animal species [109]. No metabolites have
been detected in plasma, urine,  or feces indicating a lack of either systemic or presyste‐
mic metabolism. Miglitol is eliminated by renal excretion as unchanged drug [109]. Patients
with CrCl < 25 mL/min taking the miglitol 25 mg 3 times daily exhibited a greater than 2-
fold increase in miglitol plasma levels when compared to subjects with CrCl > 60 mL/min
[109].  Dose adjustment to correct  for  the increased plasma concentrations is  not  feasible
because miglitol acts locally. However, treatment of patients with CrCl < 25 mL/min with
miglitol is not recommended because the safety of miglitol in these patients has not yet
been elucidated [109].
Glucagon-like peptide-1 analogues
The  intestinal  hormone  glucagon-like  peptide-1  (GLP-1)  stimulates  glucose-dependent
insulin  release  from  pancreatic  β-cells  in  a  glucose-dependent  manner  and  inhibits
inappropriate postprandial glucagon release. It  also shows gastric emptying and reduces
food intake. However, its meal-induced secretion is generally decreased in patients with
type 2 diabetes, and this may contribute to the amplification of postprandial hyperglyce‐
mia [72]. GLP-1 is rapidly inactivated by the enzyme dipeptidylpeptidase-4 (DPP-4) [110].
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Therefore, an effective way to potentiate postprandial GLP-1 response is the use of selective
DPP-4 inhibitors [111, 112].
Table 2 shows some of the medications in this group.
Sitagliptin is a highly selective, oral, once-daily administration DPP-4 inhibitor approved for
the treatment of patients with type 2 diabetes [113]. DPP-4 inhibitors slow the degradation
and the inactivation of the incretins, GLP-1 and glucose-dependent insulinotropic polypep‐
tide [110]. These two incretins regulate glucose homeostasis by stimulating insulin release,
while GLP-1 also suppresses glucagon release [72]. Sitagliptin can be used as initial pharma‐
cologic therapy for type 2 diabetes, as a second agent in those who do not respond to a single
agent such as a sulfonylurea [114], metformin [115-117], or a thiazolidinedione [118] and as
an additional agent when dual therapy with metformin and a sulfonylurea does not provide
adequate glycemic control [114]. CYP3A4 is the major CYP isozyme responsible for the limited
oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8. Sitaglip‐
tin  is  primarily  renally  eliminated  with  approximately  80%  of  the  oral  dose  excreted
unchanged  in  the  urine  [119,  120].  Excretion  is  thought  to  be  via  active  secretion  and
glomerular  filtration  [119,  121].  Following  single  oral  doses  of  sitagliptin,  plasma  level
increases with decreasing renal function, as determined by 24 h CrCl. Relative to subjects
with normal or mildly impaired renal function, patients with moderate renal insufficiency
(CrCl 30-50 mL/min), severe renal insufficiency (CrCl < 30 mL/min, not on dialysis) or ESRD
on  dialysis  have  approximately  2.3-fold,  3.8-fold,  or  4.5-fold  higher  plasma  sitagliptin
exposures, respectively, and the Cmax increased by 1.4-fold to 1.8-fold [122]. Tmax is significant‐
ly increased in patients with ESRD, and the terminal half-life increased with decreasing renal
function [72]. Compared with values in subjects with normal renal function, the terminal
half-life values of sitagliptin in those with mild, moderate, and severe renal impairment, and
ESRD were raised to 16.1, 19.1, 22.5 and 28.4 h, respectively, compared to 13.1 h in normal
renal function patients [122]. The fraction of dose removed by dialysis was low with 13.5%
and 3.5% for dialysis initiated at 4 and 48 h post dose, respectively. Plasma protein bind‐
ing of 38% was not altered in uremic plasma from patients with renal impairment. Based on
these data,  in  order  to  achieve plasma sitagliptin concentrations comparable  to  those in
patients  with  normal  renal  function,  sitagliptin  dose  adjustments  are  recommended  for
patients with type 2 diabetes and moderate to severe renal insufficiency, as well as for those
with ESRD requiring dialysis [123]. The usual dose of sitagliptin is 100 mg orally once daily,
with reduction to 50 mg for patients with a glomerular filtration rate of 30-50 mL/min, and
25 mg for patients with a glomerular filtration rate less than 30 mL/min [122]. Sitagliptin may
be used at does of 25 mg daily in ESRD patients, irrespective of dialysis timing. However,
some side effects have been found after administration of sitagliptin such as anaphylaxis,
angioedema and Steven-Johnson syndrome. Moreover, the risk of hypoglycemia increases
when sitagliptin is used with sulfonylureas.
Vildagliptin is not a CYP enzyme substrate and does not inhibit or induce CYP enzymes, it is
unlikely to interact with co-medications that are substrates, inhibitors, or inducers of these
enzymes [124, 125]. The efficacy of vildagliptin in humans against the DPP-4 enzyme also
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shows a low in vivo IC50 (4.5 nM), which suggests a higher potency than that reported for
sitaliptin (IC50 26 nM) [119, 126]. Elimination of vildagliptin mainly involves renal excretion of
unchanged parent drug and cyano group hydrolysis with little CYP involvement, suggesting
a low potential for drug-drug interaction when co-administered with CYP inhibitors/inducers.
In patients with mild, moderate and severe renal impairment and ESRD patients on hemo‐
dialysis, systemic exposure to vildagliptin was increased (Cmax 8-66%; AUC 32-134%) com‐
pared to subjects with normal renal function [72]. However, changes in exposure to vildagliptin
did not correlate with the severity of renal function. In contrast, exposure of the main metab‐
olite increased with increasing severity of renal function (AUC 1.6- to 6.7-fold), but this effect
has no clinically relevant consequences because the metabolite is pharmacologically inactive.
The elimination half-life of vildagliptin is not affected by renal function and it is well-tolerated
in this population [127]. According to the label, no dosage adjustment of vildagliptin is
required in patients with mild renal impairment. In clinical practice, special precautions are
advised for the use of this drug in patients with moderate to severe renal impairment, including
those on dialysis [72].
Alogliptin was rapidly absorbed and slowly eliminated primarily via urinary excretion in
healthy subjects. In patients with type 2 diabetes, alogliptin is also primarily excreted renally
with a renal clearance rate of 165-254 mL/min which is slightly higher than the normal
glomerular filtration rate, suggesting the occurrence of some active renal secretion. The results
of a single-dose (50 mg) pharmacokinetics study in patients with renal impairment showed an
increase in alogliptin exposure compared with healthy volunteers; approximately 1.7-, 2.1-,
3.2- and 3.8-fold increase in patients with mild, moderate, and severe renal impairment, and
in patients with ESRD, respectively [127, 128]. According to this data, to achieve plasma
alogliptin concentrations comparable to those in patients with normal renal function, alogliptin
dose adjustments are recommended for patients with type 2 diabetes and moderate to severe
renal insufficiency, including those with ESRD requiring dialysis [72].
Saxagliptin is another DPP-4 inhibitor and its metabolite is pharmacologically active which
makes  saxagliptin  difference  from  other  medications  in  this  group.  The  metabolism  of
saxagliptin is  primarily mediated by CYP3A4/5 and its  major metabolite  is  also a  selec‐
tive, reversible, competitive DPP-4 inhibitor which is 50% less potent than saxagliptin [129].
Saxagliptin is cleared by both metabolism and renal excretion. However, the degree of renal
impairment does not  affect  the Cmax  of  saxagliptin or  its  major metabolite  [127].  In sub‐
jects with mild renal impairment, AUC from time 0 to infinity (AUC∞) values of saxaglip‐
tin  and  its  major  metabolite  are  1.2-  and  1.7-fold  higher  than  mean  AUC∞  in  controls,
respectively,  while  they  are  1.4-  and  2.9-fold  higher  in  subjects  with  moderate  renal
impairment.  Corresponding  value  are  2.1-  and  4.5-fold  higher  in  those  with  severe
impairment [127]. A 4-h dialysis section removes approximately 23% of saxagliptin dose,
AUC∞ values for saxagliptin and its major metabolite are correlated with the degree of renal
impairment, whereas Cmax values are not well correlated. Renal function should be assessed
before initiating saxagliptin therapy and patients with moderate to severe kidney impair‐
ment should receive less than 2.5 mg of saxagliptin/day and this drug can still  be taken
after dialysis in patients with ESRD.
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Linagliptin is extensively protein bound (> 80% at the therapeutic dose) which is unlike
other DPP-4 inhibitors. Because DPP-4 is expressed in various tissues but soluble DPP-4 is
also present in plasma, binding to soluble DPP-4 may influence the pharmacokinetics of
linagliptin.  High-affinity  but  readily  saturable  binding  of  linagliptin  to  its  target  DPP-4
primarily accounted for the concentration-dependent plasma-protein binding at therapeu‐
tic plasma concentrations of linagliptin [130]. Fecal elimination is the dominant excretion
pathway of linagliptin with 84.7 and 58.2% of the dose whereas renal excretion account‐
ed for 5.4 and 30.8% of the dose administered orally or intravenously, respectively [131].
Renal  excretion of  unchanged linagliptin is  <  1% after  administration of  5  mg [132].  As
absolute  bioavailability  is  determined  to  be  around  30%,  renal  excretion  is  a  minor
elimination pathway of  linagliptin  at  therapeutic  dose  levels  (compared to  other  DPP-4
inhibitors)  and accordingly,  a  dose adjustment  in  patients  with renal  impairment  is  not
anticipated for linagliptin [72].
Incretin mimetics
GLP-1 belongs to the incretin class of  hormones which exert  an influence over multiple
physiologic functions, including a rapid blood glucose-lowering effect in response to enteral
nutrient absorption [72]. Native GLP-1 is rapidly metabolized by DPP-4 which is found in
many tissues and cell types, as well as in the circulation [133]. Clearance of native GLP-1
and  its  metabolites  is  largely  mediated  by  the  kidneys  [133].  Incretins,  such  as  GLP-1,
enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions
following their release into the circulation from the gut. Exenatide and liraglutide are GLP-1
receptor agonists  that  enhance glucose-dependent insulin secretion by pancreatic  β-cells,
suppress inappropriately elevated glucagon secretion and slow gastric emptying [72].
Exenatide is one of the drugs in this group. The amino acid sequence of exenatide is partially
homologous to that of human GLP-1. Exenatide binds and activates the human GLP-1 receptor
which leads to an increase in both glucose-dependent synthesis of insulin and secretion of
insulin from pancreatic β-cells. Exenatide is a naturally occurring GLP-1 analogue that is
resistant to degradation by DPP-4 and has a longer half-life. The kidney provides the primary
route for elimination and degradation of exenatide [134]. Given subcutaneously, exenatide
undergoes minimal systemic metabolism. In subjects with mild to moderate renal impairment
(CrCl 30-80 mL/min), exenatide exposure is similar to that of subjects with normal renal
function and no dose adjustment is required. However, in subjects with ESRD receiving
dialysis, mean exenatide exposure increased by 3.4-fold compared to that of subjects with
normal renal function. Exenatide is contraindicated in patients undergoing hemodialysis,
ESRD or in patients who have glomerular filtration rate less than 30 mL/min and it should be
used with caution in patients undergone renal transplantation [135]. In patients with ESRD
receiving dialysis, single dose of 5 μg exenatide are not well tolerated due to gastrointestinal
side effects. Due to the side effects of exenatide such as nausea and vomiting with transient
hypovolemia, treatment may worsen renal function. Caution is required when initiating or
escalating doses of exenatide from 5 μg to 10 μg in patients with moderate renal impairment
(CrCl 30-50 mL/min) [72].
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Liraglutide is a once-daily human GLP-1 analog and has a high degree of sequence identity
to human GLP-1 [136, 137]. The half-life of liraglutide is approximately 13 h after subcuta‐
neous injection [138] and its metabolism is similar to that of large peptides which is fully
degraded  in  the  body  [137].  There  is  no  evidence  that  kidney  is  a  major  organ  for
elimination.  Its  pharmacokinetics  parameters  are  essentially  independent  of  renal  func‐
tion [139]. Renal dysfunction is not found to increase exposure of liraglutide and patients
with  type  2  diabetes  and  renal  impairment  can  be  treated  with  standard  regimens  of
liraglutide [72].
Amylin analogs
Currently, pramlintide is the only drug in this group which is administered by subcutaneous
injection and it is a naturally occurring neuroendocrine hormone co-secreted with insulin by
pancreatic β-cells [140]. Amylin regulates gastric emptying [141], suppresses inappropriate
postprandial glucagon secretion [142] and reduces food intake [143]. Through the mechanism
similar to those of amylin, pramlintide reduces postprandial glucose, improving overall
glycemic control [144, 145] and increases satiety resulting in reduced food intake and weight
loss [146-148]. The half-life of pramlintide in healthy subjects, which is metabolized primarily
by the kidney, is approximately 48 min. Its primary metabolite has a similar half-life and is
biologically active. Patients with moderate or severe renal impairment (CrCl > 20 to < 50 mL/
min) do not show increased pramlintide exposure or reduced pramlintide clearance when
compared with subjects with normal renal function. However, no data is available for dialysis
patients and further clinical studies are warranted in this population.
Sodium glucose co-transporter 2 (SGLT2) inhibitors
The plasma glucose level below which nearly all filtered glucose is reabsorbed by the kidneys,
and above which glucose is excreted in urine, is designated as the renal threshold for glucose
(RTG) [149]. In healthy individuals, virtually all filtered glucose is reabsorbed up to a plasma
glucose level of approximately 10 mmol/L (180 mg/dL), thus defining RTG [150, 151]. At plasma
glucose levels higher than RTG, the renal glucose reabsorptive capacity is saturated and the
amount of glucose in urine increases proportionately to plasma glucose concentration [152].
By inhibiting the proximal renal tubule glucose transporter responsible for the majority of
glucose reabsorption, sodium glucose co-transporter 2 (SGLT2) inhibitors are predicted to
lower RTG, thereby increasing urinary glucose excretion [149]. In patients with diabetes,
reduction of RTG is expected to increase urinary glucose excretion and lower plasma glucose
concentrations. Unlike other antidiabetic agents which often cause weight gain, the glucose-
lowering effect with SGLT2 inhibitors is accompanied by urinary loss of calories, potentially
resulting in weight loss. Moreover, SGLT2 inhibitors do not target the major pathophysiolog‐
ical defects in type 2 diabetes mellitus-namely insulin resistance and impaired insulin
secretion-they represent a potentially promising new option in the treatment of diabetes [153].
One of the drug in this category is canagliflozin. In preclinical studies, a single oral adminis‐
tration of 3 mg/kg of canagliflozin decreased plasma glucose levels independent of food intake
in mice on a high-fat, hyperglycemic diet [153]. In normo-glycemic mice, canagliflozin
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administration led to a minimal change in plasma glucose levels. Sha et al. show that canagli‐
flozin was well tolerated in healthy men across the range of single does studied up to 800 mg.
By inhibiting SGLT2, canagliflozin treatment dose dependently decreased RTG, leading to a
dose-dependent increase in urinary glucose excretion [149]. However, no data on its safety
and efficacy is available for CKD or dialysis patients and further clinical studies are warranted
in this population.
7. Combination therapy
Saxagliptin plus metformin
In order to obtain the better control of plasma glucose level and decrease the side effect of
some medications in renal patients, combination therapy has been used. Scheen reviewed
the use of metformin plus saxagliptin in renal impairment patients [154]. Since saxaglip‐
tin’s  license was recently extended to include diabetic  patients  with moderate or  severe
renal impairment while metformin is still widely prescribed in patients with some degree
of renal impairment in real life even though it  is  contraindicated, the pro and contra of
using  this  combination  in  type  2  diabetic  patients  with  renal  impairment  need  to  be
reviewed. Some recent data suggested that both metformin and saxagliptin may be used
safely in type 2 diabetic patients with mild-to-moderate renal impairment, provided that
dose reduction is made appropriately according to individual CrCl [154].  Because of the
absence of pharmacokinetics interactions between the two drugs, this should be also the
case with the saxagliptin-metformin combination. In this population, DPP-4 inhibitors offer
advantages compared with sulfonylureas, especially because of the absence of hypoglyce‐
mia [155, 156]. A retrospective subgroup analysis of data from five randomized, double-
blind, placebo-controlled, multicenter, 24-week, Phase III trials showed that saxagliptin 5
mg once-daily monotherapy and as add-on therapy are associated with clinically relevant
and significant efficacy for reducing hemoglobin A1c  in older patients  (≥ 65 years;  CrCl:
80±20 mL/min) versus younger patients (< 65 years; CrCl: 119±40 mL/min) [157]. Further‐
more, saxagliptin was well-tolerated in older patients with a low incidence of hypoglyce‐
mia and no weight gain. Normally, patients with type 2 diabetes and renal impairment are
exposed to a higher risk of cardiovascular disease. Therefore, reducing cardiovascular risk
in this population should be considered as a main objective and drugs that have proven
their efficacy and safety in this regard should be preferred. Treatment with metformin in
type 2 diabetic patients is associated with a lower cardiovascular morbidity and mortali‐
ty, compared with alternative glucose-lowering drugs [158]. It has also been suggested that
metformin might exert  direct  protective effects on the heart  [159].  Since both metformin
and saxagliptin are excreted via the kidney, dose adjustment is required in case of moderate-
to-severe renal impairment (ca. half dose of saxagliptin). Due to major discrepancies exist
between guidelines (metformin excluded in case of renal impairment because of the risk of
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lactic acidosis) and real life, physicians should weigh the benefit/risk ratio carefully before
deciding to prescribe or withdraw this combination in renal patients.
DDP-4 inhibitor plus thiazolidinedione
Thiazolidinediones  are  currently  considered  as  the  most  efficacious  class  of  oral  anti-
diabetics [160]. However, they carry the burden of weight gain and hemodilution which
may lead to cardiovascular complications. It has been considered that the use of a low dose
thiazolidinedione  in  combination  with  DPP-4  inhibitor  may  reduce  the  risk  of  dose
dependent side effects of thiazolidinediones such as weight gain and hemodilution while,
simultaneously, this combination may be more effective owing to different mechanisms of
action of thiazolidinediones and DPP-4 inhibitors. Roy et al. demonstrated that in aged db/
db  mice,  a  combination  therapy  of  low dose  rosiglitazone  and vildagliptin  is  safer  and
equally  efficacious  when  compared  to  the  therapeutic  dose  of  rosiglitazone  [160].  The
combination  therapy  (1  mg/kg/day  of  rosiglitazone  plus  5  mg/kg/day  of  vildagliptin)
showed similar efficacy as that of 10 mg/kg/day rosiglitazone in lowering random blood
glucose. GLP-1 and insulin levels were found to be elevated significantly in both vildaglip‐
tin and combination treated groups following oral glucose load. Vildagliptin alone had no
effect  on  random  glucose  and  glucose  excursion  during  oral  glucose  tolerance  test  in
severely diabetic db/db mice. The combination treatment showed no significant increase in
body weight as compared to the robust weight gain by therapeutic dose of rosiglitazone.
Rosiglitazone at 10 mg/kg/day showed significant reduction in hematocrit, red blood cell
count,  hemoglobin  pointing  towards  hemodilution  associated  with  increased  mRNA
expression  of  Na+,  K+-ATPase-α  and  epithelial  sodium  channel  gamma  in  kidney.  The
combination therapy escaped these adverse effects. The results suggest that combination of
DPP-4 inhibitor with low dose thiazolidinedione can interact synergistically to represent a
therapeutic  advantage  for  the  clinical  treatment  of  type  2  diabetes  without  the  adverse
effects of haemodilution and weight gain associated with thiazolidinediones.
DDP-4 plus metformin
The retrospective analysis by Banerji et al. found that the combination of vildagliptin and
metformin in  type 2  diabetic  patients  with mild renal  impairment  is  safe  and tolerable,
similar to that in patients with normal renal function [161]. Furthermore these results were
similar to those in patients receiving a combination of thiazolidinedione and metformin.
Higher incidence of  headache and rash was noted in both vildagliptin groups,  whereas
those  with  mild  renal  impairment  receiving  thiazolidinedione  experienced  a  higher
incidence of peripheral edema.
Mitiglinide plus voglibose
Unlike typical sulfonylurea agents, mitiglinide, a benzylsuccinic acid derivative, is a rapid-
and short-acting insulinotropic sulfonylurea receptor ligand with rapid hypoglycemic action.
It alleviates postprandial hyperglycemia and, as a result, improves overall glycemic control
[162]. The blood concentration of mitiglinide rapidly increases after oral administration and
the drug quickly disappears subsequently; therefore, it is unlikely to exert hypoglycemic
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
175
effects early in the morning and between meals. Abe et al. demonstrated that add-on therapy
of mitiglinide with voglibose may be a therapeutic option for achieving good glycemic control
in type 2 diabetic hemodialysis patients with otherwise poor glycemic control [86]. The daily
dose of mitiglinide is suggested to be lower in the diabetic hemodialysis patients than that in
the diabetic patients with normal kidney function. At low dose (23 mg), mitiglinide was
adequate to induce significant reductions in glycemic parameters such as fasting plasma
glucose, hemoglobin A1c, glycated albumin levels and HOMA-IR. Mitiglinide also significantly
improved glycemic control, triglyceride level and interdialytic weight gain even when it was
administered only for a short duration [86].
8. Effects of high-flux dialyzer membranes on plasma insulin
Nowadays, several types of high-flux dialyzer membranes are on the market. The normal‐
ly used ones are made from polysulfone, polyethersulfone, cellulose triacetate, polymethyl‐
methacrylate or  polyester-polymer alloy.  The mechanism of  plasma insulin clearance by
hemodialysis is mainly by adsorption rather than diffusion or convection since no insulin
is not normally detected in either the dialysate or the ultrafiltrate fluid during hemodialy‐
sis  [163].  Furthermore,  the  amount  of  insulin  adsorbed  differed  depending  on  the  dia‐
lyzer  membrane  used.  The  insulin  levels  during  a  dialysis  session  depend not  only  on
insulin  removal  by  dialysis  but  also  on  the  secretion  of  insulin  from  the  pancreatic  β-
cells; this in turn is determined by the changes in plasma glucose induced by dialysis and
the  ability  of  the  β-cells  to  respond  to  these  glucose  changes  [163].  Therefore,  it  was
suggested  that  an  increase  in  endogenous  insulin  secretion  may  occur  in  response  to
hemodialysis treatment, in particular with the polysulfone membrane. On the other hand,
plasma glucose levels  at  the post-dialysis  stage were mainly determined by the glucose
concentration in the dialysate; this is because the molecular weight of glucose is very small,
and glucose  rapidly  transmigrates  across  the  membrane during hemodialysis  treatment.
Therefore, plasma glucose levels at the post-dialysis stage should be similar in the case of
polysulfone, cellulose triacetate and polyester polymer alloy membranes, regardless of the
type of high-flux membrane. However, in the insulin-dependent diabetes mellitus (IDDM)
subjects, who lack endogenous insulin secretion, the insulin reduction rate was significant‐
ly higher when the polysulfone membrane was used compared with the cellulose triace‐
tate and polyester-polymer alloy membranes. This is because these patients have no residual
β-cell function, which is responsible for insulin secretion; therefore, if plasma insulin was
removed by hemodialysis, these cells could not have maintained the patients’ insulin levels.
Hence,  plasma insulin removal  is  highly significant in the case of  diabetic  hemodialysis
patients  with  low C-peptide  levels,  particularly  those  with  type  1  or  2  diabetes  with  a
deteriorated β-cell  function [164].  Higher doses of  injected insulin or antidiabetic  agents
might be added in order to achieve good glycemic control in such patients,  because the
surplus insulin is removed by hemodialysis, particularly when the polysulfone dialyzer is
used [163]. Therefore, patient monitoring of blood glucose on the day that hemodialysis is
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performed could be useful for self-assessment of glycemic state, and if hyperglycemia was
recognized, and additional dose of injected insulin after hemodialysis should be considered.
Due to the development in dialyzer technology, it was found that the biocompatible dialyzer
membrane  used  in  hemodialysis  patients  not  only  causes  less  hemodialysis-induced
inflammation but also achieves better  clearance of  uremic toxins and medium- to large-
sized molecules [165].  Moreover,  high-flux dialyzers have been shown to be superior in
terms of attenuating hyperlipidemia and alleviating oxidative stress [166, 167]. There is a
significant reduction in patients’ plasma insulin at different time point with each type of
membranes, because various biological reactions can occur in the course of contact between
artificial  materials  and  blood  components  in  the  extracorporeal  circulation  [163].  The
clearance  of  plasma  immunoreactive  insulin  (IRI),  a  biologically  active  molecule,  is
significantly higher in patients used polysulfone membrane than by other membranes such
as polyethersulfone, cellulose triacetate, polymethylmethacrylate or polyester-polymer alloy
[168].  Moreover,  no  clinical  difference  has  been  found  in  the  reduction  rate  of  IRI  be‐
tween hemodialysis treatments when using either polysulfone, polyethersulfone, cellulose
triacetate or polymethylmethacrylate except for polyester-polymer alloy [168]. From these
results, it  suggests that hemodialysis patients with residual β-cell function, the course of
treatment for diabetic control  would be unaffected by the differences resulting from the
type of membrane used. However, in diabetic hemodialysis patients, particularly in type 1
and type 2 with deteriorated β-cell  function,  these differences might be very significant.
Higher  doses  of  injected insulin might  be required to  achieve good glycemic control  in
hyperinsulinemic  patients  because  the  surplus  insulin  is  removed  by  hemodialysis,
specifically by polysulfone,  polyethersulfone,  cellulose triacetate or  polymethylmethacry‐
late, excluding polyester-polymer alloy membrane dialyzer. Polysulfone membrane dialyzer
may  worsen  glycemic  control  and  switching  to  the  polyester-polymer  alloy  membrane
dialyzer which shows a lower IRI clearance rate might improve the glycemic control  in
hemodialysis patients.
9. Conclusion
Although diabetes is the most common cause of ESRD and diabetic control is considered as
one of the most important factor to prolong patients’ life and improve their quality of life, data
are scarce on how diabetes should be best treated in patients with CKD or ESRD. Since the
glycemic control and monitoring in CKD and ESRD patients is complex, patient education is
also one of the key factors for successful treatment. Moreover, patients with diabetic nephr‐
opathy are especially susceptible to hypoglycemia and diabetic drug therapy requires special
caution. Adjustment of the type of drugs used or dosage regimen should be individualized
based on self-monitored blood glucose patterns.
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
177
Acknowledgements
We are grateful for the support from The Thailand Research Fund and Bentham Science
Publishers for permission of copyrighted material (Table 2).
Author details
Pornanong  Aramwit1* and Bancha  Satirapoj2
*Address all correspondence to: aramwit@gmail.com
1 Bioactive Resources for Innovative Clinical Applications Research Unit and Department of
Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phaya‐
Thai Road, Phatumwan, Bangkok, Thailand
2 Division of Nephrology, Phramongkutklao Hospital and College of Medicine, Bangkok,
Thailand
References
[1] Praditpornsilpa K, Lekhyananda S, Premasathian N, Kingwatanakul P, Lumpaopong
A, Gojaseni P, et al. Prevalence trend of renal replacement therapy in Thailand: im‐
pact of health economics policy. J Med Assoc Thai. 2011;94 Suppl 4 S1-6.
[2] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence,
numerical estimates, and projections. Diabetes Care. 1998;21(9) 1414-1431.
[3] Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of
chronic kidney disease in the United States. JAMA. 2007;298(17) 2038-2047.
[4] Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J
Med Assoc Thai. 2010;93 Suppl 6 S228-241.
[5] Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. 'United
States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease
& end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1)
A7, e1-420.
[6] Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease
among individuals with diabetes in the U.S. continues to decline. Diabetes Care.
2010;33(1) 73-77.
Hemodialysis178
[7] Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, et al. Inci‐
dence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with
and without diabetic nephropathy in Finland. Diabetologia. 1998;41(7) 784-790.
[8] Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development
and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective
Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1) 225-232.
[9] Incidence of end-stage renal disease attributed to diabetes among persons with diag‐
nosed diabetes --- United States and Puerto Rico, 1996-2007. MMWR Morb Mortal
Wkly Rep. 2010;59(42) 1361-1366.
[10] Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal re‐
placement therapy for diabetic end-stage renal disease: data from 10 registries in Eu‐
rope (1991-2000). Kidney Int. 2005;67(4) 1489-1499.
[11] KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Dia‐
betes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2) S12-154.
[12] Mishra R, Emancipator SN, Kern T, Simonson MS. High glucose evokes an intrinsic
proapoptotic signaling pathway in mesangial cells. Kidney Int. 2005;67(1) 82-93.
[13] Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression
of glucose transporters in rat mesangial cells cultured in a normal glucose milieu
mimics the diabetic phenotype. J Clin Invest. 1995;96(4) 1802-1814.
[14] Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin
Dial. 2000;13(1) 4-8.
[15] Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin re‐
sistance as an independent predictor of cardiovascular mortality in patients with
end-stage renal disease. J Am Soc Nephrol. 2002;13(7) 1894-1900.
[16] Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4)
453-458.
[17] Satirapoj B, Supasyndh O, Dispan R, Punpanich D, Tribanyatkul S, Choovichian P.
Insulin Resistance and Type 2 Diabetes Patients in Difference Stage of Nephropathy.
Royal Thai Army Medical Journal. 2009;62(3) 113-122.
[18] Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance in adult poly‐
cystic kidney disease. Kidney Int. 1997;52(2) 503-508.
[19] Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. Insulin
resistance and hyperinsulinemia are already present in patients with incipient renal
disease. Kidney Int. 1998;53(5) 1343-1347.
[20] Satirapoj B, Supasyndh O, Boonyavarakul A, Luesutthiviboon L, Choovichian P. The
correlation of insulin resistance and renal function in non diabetic chronic kidney
disease patients. J Med Assoc Thai. 2005;88 Suppl 3 S97-104.
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
179
[21] DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quanti‐
fication of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J
Clin Invest. 1978;62(2) 425-435.
[22] Hong SY, Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage
renal disease. Nephron. 1994;68(3) 329-333.
[23] Satirapoj B, Supasyndh O, Phantana-Angkul P, Ruangkanchanasetr P, Nata N, Chai‐
prasert A, et al. Insulin resistance in dialysis versus non dialysis end stage renal dis‐
ease patients without diabetes. J Med Assoc Thai. 2011;94 Suppl 4 S87-93.
[24] Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and hy‐
perinsulinemia in uremia. Am J Physiol. 1996;270(5 Pt 2) F839-844.
[25] Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron.
1992;61(4) 377-382.
[26] Satirapoj B, Yingwatanadej P, Chaichayanon S, Patumanond J. Effect of angiotensin
II receptor blockers on insulin resistance in maintenance haemodialysis patients.
Nephrology (Carlton). 2007;12(4) 342-347.
[27] Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insu‐
lin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int. 2009;29
Suppl 2 S145-148.
[28] Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North
Am. 1989;18(1) 103-121.
[29] Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care.
2002;6(4) 317-321.
[30] Effect of intensive diabetes treatment on the development and progression of long-
term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes
Control and Complications Trial. Diabetes Control and Complications Trial Research
Group. J Pediatr. 1994;125(2) 177-188.
[31] Intensive blood-glucose control with sulphonylureas or insulin compared with con‐
ventional treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131)
837-853.
[32] Kawazu S, Tomono S, Shimizu M, Kato N, Ohno T, Ishii C, et al. The relationship be‐
tween early diabetic nephropathy and control of plasma glucose in non-insulin-de‐
pendent diabetes mellitus. The effect of glycemic control on the development and
progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Com‐
plications. 1994;8(1) 13-17.
Hemodialysis180
[33] The effect of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. The Diabetes Con‐
trol and Complications Trial Research Group. N Engl J Med. 1993;329(14) 977-986.
[34] Mulec H, Blohme G, Grande B, Bjorck S. The effect of metabolic control on rate of de‐
cline in renal function in insulin-dependent diabetes mellitus with overt diabetic
nephropathy. Nephrol Dial Transplant. 1998;13(3) 651-655.
[35] Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of di‐
abetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2) 69-75.
[36] Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and
tubular lesions in pancreas transplant recipients. Kidney Int. 2006;69(5) 907-912.
[37] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of inten‐
sive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15) 1577-1589.
[38] Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of
intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24) 2545-2559.
[39] Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive
blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl
J Med. 2008;358(24) 2560-2572.
[40] Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose
control and vascular complications in veterans with type 2 diabetes. N Engl J Med.
2009;360(2) 129-139.
[41] Drechsler C, Krane V, Ritz E, Marz W, Wanner C. Glycemic control and cardiovascu‐
lar events in diabetic hemodialysis patients. Circulation. 2009;120(24) 2421-2428.
[42] Tsujimoto Y, Ishimura E, Tahara H, Kakiya R, Koyama H, Emoto M, et al. Poor glyce‐
mic control is a significant predictor of cardiovascular events in chronic hemodialysis
patients with diabetes. Ther Apher Dial. 2009;13(4) 358-365.
[43] Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measure‐
ments in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39(2)
297-307.
[44] Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, et al. Glycosylated he‐
moglobin and mortality in patients with nondiabetic chronic kidney disease. J Am
Soc Nephrol. 2005;16(11) 3411-3417.
[45] Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, et al.
A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30(5)
1049-1055.
[46] Williams ME, Lacson E, Jr., Wang W, Lazarus JM, Hakim R. Glycemic control and
extended hemodialysis survival in patients with diabetes mellitus: comparative re‐
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
181
sults of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol.
2010;5(9) 1595-1601.
[47] Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, et al. Glycemic
control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year
cohort study. Diabetes. 2012;61(3) 708-715.
[48] McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care man‐
agement significantly improve patient outcomes in the dialysis unit. Am J Kidney
Dis. 2002;40(3) 566-575.
[49] Standards of medical care in diabetes--2012. Diabetes Care. 2012;35 Suppl 1 S11-63.
[50] Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defin‐
ing the relationship between plasma glucose and HbA(1c): analysis of glucose pro‐
files and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care.
2002;25(2) 275-278.
[51] Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albu‐
min is a better glycemic indicator than glycated hemoglobin values in hemodialysis
patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Neph‐
rol. 2007;18(3) 896-903.
[52] Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabe‐
tes and end-stage renal failure. Am J Kidney Dis. 2003;41(3) 523-531.
[53] Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, et al. Com‐
parison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects
on peritoneal and hemodialysis. Peritoneal dialysis international : journal of the In‐
ternational Society for Peritoneal Dialysis. 2010;30(1) 72-79.
[54] Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Com‐
parison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on he‐
modialysis. Kidney Int. 2008;73(9) 1062-1068.
[55] Freedman BI, Shihabi ZK, Andries L, Cardona CY, Peacock TP, Byers JR, et al. Rela‐
tionship between assays of glycemia in diabetic subjects with advanced chronic kid‐
ney disease. Am J Nephrol. 2010;31(5) 375-379.
[56] Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM. Tests of
glycemia in diabetes. Diabetes Care. 2004;27 Suppl 1 S91-93.
[57] Shrishrimal K, Hart P, Michota F. Managing diabetes in hemodialysis patients: obser‐
vations and recommendations. Cleve Clin J Med. 2009;76(11) 649-655.
[58] Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal
tubule. Am J Physiol. 1980;238(3) F151-158.
[59] Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake
and excretion of insulin in man. N Engl J Med. 1970;282(4) 182-187.
Hemodialysis182
[60] DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin re‐
sistance in uremia. J Clin Invest. 1981;67(2) 563-568.
[61] Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin require‐
ment in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic
patients. Diabet Med. 2003;20(8) 642-645.
[62] Avram MM, Paik SK, Okanya D, Rajpal K. The natural history of diabetic nephrop‐
athy: unpredictable insulin requirements--a further clue. Clin Nephrol. 1984;21(1)
36-38.
[63] Williams ME. Management of diabetes in dialysis patients. Curr Diab Rep. 2009;9(6)
466-472.
[64] Aisenpreis U, Pfutzner A, Giehl M, Keller F, Jehle PM. Pharmacokinetics and phar‐
macodynamics of insulin Lispro compared with regular insulin in haemodialysis pa‐
tients with diabetes mellitus. Nephrol Dial Transplant. 1999;14 Suppl 4 5-6.
[65] Smith D, DeFronzo RA. Insulin resistance in uremia mediated by postbinding de‐
fects. Kidney Int. 1982;22(1) 54-62.
[66] Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic in‐
sulin-dependent diabetic subjects. Diabetes. 1985;34(11) 1152-1159.
[67] Wong TY, Chan JC, Szeto CC, Leung CB, Li PK. Clinical and biochemical characteris‐
tics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relation‐
ships with insulin requirement. Am J Kidney Dis. 1999;34(3) 514-520.
[68] Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron.
1975;15(3-5) 306-326.
[69] Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insu‐
lin resistance and glucose homeostasis in peritoneal dialysis. Peritoneal dialysis in‐
ternational : journal of the International Society for Peritoneal Dialysis. 2009;29 Suppl
2 S145-148.
[70] Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. New-onset hypergly‐
cemia in nondiabetic chinese patients started on peritoneal dialysis. Am J Kidney
Dis. 2007;49(4) 524-532.
[71] Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing iso‐
smolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study
Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis.
Kidney Int. 1994;46(2) 496-503.
[72] Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney dis‐
ease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr
Drug Metab. 2011;12(1) 57-69.
[73] Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, et
al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
183
end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care.
2010;33(7) 1409-1412.
[74] Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with
type 2 diabetes mellitus. Nephrol Dial Transplant. 2006;21(2) 553-554.
[75] Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood
glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26 Suppl 4 73-85.
[76] Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T, Suzuki D. Insulin
glargine improves glycemic control and quality of life in type 2 diabetic patients on
hemodialysis. J Nephrol. 2012;25(6) 989-995.
[77] Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts.
J Am Soc Nephrol. 2005;16 Suppl 1 S7-10.
[78] Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in
diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000;35(3) 500-505.
[79] Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacoki‐
netics and safety of glimepiride at clinically effective doses in diabetic patients with
renal impairment. Diabetologia. 1996;39(12) 1617-1624.
[80] Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients
with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17(5) 365-370.
[81] United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of ran‐
domly allocated diet, sulphonylurea, insulin, or metformin in patients with newly di‐
agnosed non-insulin dependent diabetes followed for three years. BMJ.
1995;310(6972) 83-88.
[82] Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide adminis‐
tration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract.
2003;59(3) 191-194.
[83] Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, et al. Pharma‐
cokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus
and renal failure. Clin Nephrol. 2003;60(2) 90-95.
[84] Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1,
Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J
Pharmacol. 2001;132(7) 1542-1548.
[85] Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y. Effect of mitiglinide on glyce‐
mic control over 52 weeks in Japanese type 2 diabetic patients insufficiently control‐
led with pioglitazone monotherapy. Endocr J. 2009;56(6) 739-746.
[86] Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Combination therapy
with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients
on hemodialysis. Expert Opin Pharmacother. 2010;11(2) 169-176.
Hemodialysis184
[87] Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Efficacy and safety of
mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J. 2010;57(7)
579-586.
[88] Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Dis‐
position of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther.
1978;24(6) 683-693.
[89] http://www.sanofi-aventis.ca/products/en/glucophage.pdf, Accessed 5th August,
2012.
[90] Martin Gomez MA, Sanchez Martos MD, Garcia Marcos SA, Serrano Carrillo de Al‐
bornoz JL. Metformin-induced lactic acidosis: usefulness of measuring levels and
therapy with high-flux haemodialysis. Nefrologia. 2011;31(5) 610-611.
[91] Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces
insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving
peritoneal dialysis. Am J Kidney Dis. 2005;46(4) 713-719.
[92] Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM. Regulation of glucose
transport in cultured muscle cells by novel hypoglycemic agents. Metabolism.
1995;44(8) 976-981.
[93] Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Diabetes. 1998;47(4) 507-514.
[94] Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Drugs. 2005;65(3) 385-411.
[95] Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglita‐
zone in patients with end-stage renal disease. J Int Med Res. 2002;30(4) 391-399.
[96] Goldstein BJ. Rosiglitazone. Int J Clin Pract. 2000;54(5) 333-337.
[97] Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al. Absorption,
disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sen‐
sitizer, in humans. Drug Metab Dispos. 2000;28(7) 772-780.
[98] Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. The phar‐
macokinetics of pioglitazone in patients with impaired renal function. Br J Clin Phar‐
macol. 2003;55(4) 368-374.
[99] Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidine‐
dione use, fluid retention, and congestive heart failure: a consensus statement from
the American Heart Association and American Diabetes Association. Diabetes Care.
2004;27(1) 256-263.
[100] Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in re‐
nal disease. Eur J Endocrinol. 2006;154(5) 613-621.
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
185
[101] Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assess‐
ment from bench to bedside. Kidney Int. 2006;70(7) 1223-1233.
[102] Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabo‐
lism in nondiabetic uremic patients on CAPD. Am J Kidney Dis. 2003;42(4) 774-780.
[103] Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and addi‐
tional vascular effects of thiazolidinediones. Drugs. 2002;62(10) 1463-1480.
[104] Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a
sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate
renal impairment: a post hoc analysis. Clin Ther. 2003;25(11) 2754-2764.
[105] Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of
oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999;6(5)
337-346.
[106] Chiang CK, Ho TI, Peng YS, Hsu SP, Pai MF, Yang SY, et al. Rosiglitazone in diabetes
control in hemodialysis patients with and without viral hepatitis infection: effective‐
ness and side effects. Diabetes Care. 2007;30(1) 3-7.
[107] Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K. Clinical effec‐
tiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin
responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Ex‐
pert Opin Pharmacother. 2010;11(10) 1611-1620.
[108] http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020482s023lbl.pdf, Ac‐
cessed 5th August, 2012.
[109] http://www.pfizer.com/files/products/uspi_glyset.pdf, Accessed 5th August, 2012.
[110] Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor ago‐
nists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548)
1696-1705.
[111] Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4
(DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008(2)
CD006739.
[112] Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral anti‐
diabetic drug. Diabetes Obes Metab. 2007;9(2) 153-165.
[113] Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors
for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther.
2007;81(5) 761-767.
[114] Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety
of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes
mellitus inadequately controlled on glimepiride alone or on glimepiride and metfor‐
min. Diabetes Obes Metab. 2007;9(5) 733-745.
Hemodialysis186
[115] Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the
dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipi‐
zide, in patients with type 2 diabetes inadequately controlled on metformin alone: a
randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2)
194-205.
[116] Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of
initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and
metformin on glycemic control in patients with type 2 diabetes. Diabetes Care.
2007;30(8) 1979-1987.
[117] Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the di‐
peptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in pa‐
tients with type 2 diabetes inadequately controlled with metformin alone. Diabetes
Care. 2006;29(12) 2638-2643.
[118] Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptid‐
yl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients
with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-con‐
trolled, parallel-group study. Clin Ther. 2006;28(10) 1556-1568.
[119] Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmaco‐
kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase
IV, in healthy subjects: results from two randomized, double-blind, placebo-control‐
led studies with single oral doses. Clin Pharmacol Ther. 2005;78(6) 675-688.
[120] Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral
doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glu‐
cose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin
Endocrinol Metab. 2006;91(11) 4612-4619.
[121] Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipep‐
tidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic
anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J
Pharmacol Exp Ther. 2007;321(2) 673-683.
[122] Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insuffi‐
ciency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Dia‐
betes Care. 2007;30(7) 1862-1864.
[123] Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, et al. Safety
and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insuffi‐
ciency. Diabetes Obes Metab. 2008;10(7) 545-555.
[124] Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2
diabetes mellitus. Drugs. 2008;68(16) 2387-2409.
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
187
[125] Henness S, Keam SJ. Vildagliptin. Drugs. 2006;66(15) 1989-2001; discussion
2002-1984.
[126] He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, et al. Pharmacokinet‐
ics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Clin Pharmacokinet. 2007;46(7) 577-588.
[127] Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Met‐
ab. 2010;12(8) 648-658.
[128] Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for
the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009;10(3) 503-512.
[129] Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, et al. Pharmacoki‐
netics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys
and clinical projections. Drug Metab Dispos. 2009;37(6) 1164-1171.
[130] Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plas‐
ma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to satu‐
rable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol.
2009;61(1) 55-62.
[131] Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metab‐
olism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in hu‐
mans. Drug Metab Dispos. 2010;38(4) 667-678.
[132] Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, phar‐
macokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of
dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10)
1171-1178.
[133] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology.
2007;132(6) 2131-2157.
[134] Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of
exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab.
2006;7(4) 367-374.
[135] Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal
impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64(3)
317-327.
[136] Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al.
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suita‐
ble for once daily administration. J Med Chem. 2000;43(9) 1664-1669.
[137] Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et
al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 ana‐
Hemodialysis188
log liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl
peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11) 1944-1953.
[138] Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics,
pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 de‐
rivative, in healthy men. Diabetologia. 2002;45(2) 195-202.
[139] Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on
the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol.
2009;68(6) 898-905.
[140] Young A. Inhibition of glucagon secretion. Adv Pharmacol. 2005;52 151-171.
[141] Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in
diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia.
1995;38(6) 642-648.
[142] Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin
in rats. Metabolism. 1997;46(1) 67-70.
[143] Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a
chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the
solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord. 2001;25(7)
1005-1011.
[144] Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin re‐
placement with pramlintide as an adjunct to insulin therapy improves long-term gly‐
caemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized
controlled trial. Diabet Med. 2004;21(11) 1204-1212.
[145] Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A
randomized study and open-label extension evaluating the long-term efficacy of
pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care.
2002;25(4) 724-730.
[146] Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, et al. Pramlintide improved
glycemic control and reduced weight in patients with type 2 diabetes using basal in‐
sulin. Diabetes Care. 2007;30(11) 2794-2799.
[147] Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlin‐
tide as an adjunct to insulin therapy improves long-term glycemic and weight con‐
trol in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes
Care. 2003;26(3) 784-790.
[148] Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, et al. Effect of
pramlintide on satiety and food intake in obese subjects and subjects with type 2 dia‐
betes. Diabetologia. 2005;48(5) 838-848.
[149] Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canagliflozin, a
novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calcu‐
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
189
lated renal threshold for glucose excretion and increases urinary glucose excretion in
healthy subjects. Diabetes Obes Metab. 2011;13(7) 669-672.
[150] Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose ex‐
cretion as a function of blood glucose concentration in subjects with type 2 diabetes--
results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant.
2006;21(8) 2166-2171.
[151] Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for
diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1) 34-42.
[152] Ruhnau B, Faber OK, Borch-Johnsen K, Thorsteinsson B. Renal threshold for glucose
in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1997;36(1) 27-33.
[153] Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat
Rev Drug Discov. 2010;9(7) 551-559.
[154] Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes
and renal impairment. Expert Opin Drug Metab Toxicol. 2012;8(3) 383-394.
[155] Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic
review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr
Pharmacother. 2011;8(5) 405-418.
[156] Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management
of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap). 2011;39(1)
7-21.
[157] Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of
saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin.
2011;27(4) 863-869.
[158] Effect of intensive blood-glucose control with metformin on complications in over‐
weight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study
(UKPDS) Group. Lancet. 1998;352(9131) 854-865.
[159] El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of
metformin. Curr Opin Lipidol. 2011;22(6) 445-453.
[160] Roy S, Khanna V, Mittra S, Dhar A, Singh S, Mahajan DC, et al. Combination of di‐
peptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy
and safety in db/db mice. Life Sci. 2007;81(1) 72-79.
[161] Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs.
thiazolidinedione as add-on to metformin in type 2 diabetic patients with and with‐
out mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes
Res Clin Pract. 2010;90(2) 182-190.
[162] Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, et al. The effects of
mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and
Hemodialysis190
insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharma‐
col. 2001;431(1) 119-125.
[163] Abe M, Okada K, Ikeda K, Matsumoto S, Soma M, Matsumoto K. Characterization of
insulin adsorption behavior of dialyzer membranes used in hemodialysis. Artif Or‐
gans. 2011;35(4) 398-403.
[164] Abe M, Okada K, Maruyama T, Ikeda K, Kikuchi F, Kaizu K, et al. Comparison of the
effects of polysulfone and polyester-polymer alloy dialyzers on glycemic control in
diabetic patients undergoing hemodialysis. Clin Nephrol. 2009;71(5) 514-520.
[165] Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, et al. Effects of hemodialy‐
sis dose and membrane flux on health-related quality of life in the HEMO Study.
Kidney Int. 2004;66(1) 355-366.
[166] Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux
dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc
Nephrol. 1995;5(9) 1703-1708.
[167] Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma
lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993;3(7) 1409-1415.
[168] Abe M, Okada K, Matsumoto K. Plasma insulin and C-peptide concentrations in dia‐
betic patients undergoing hemodialysis: Comparison with five types of high-flux dia‐
lyzer membranes. Diabetes Res Clin Pract. 2008;82(1) e17-19.
Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
http://dx.doi.org/10.5772/52479
191

